Methods for the treatment of her2 amplified cancer

Abstract

Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.

1 . A method for treating HER2 amplified breast cancer in an individual in need thereof comprising administering to an individual in need thereof a composition comprising (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one 
       
         
           
           
               
               
           
         
       
     
     
         10 - 21 . (canceled) 
     
     
         22 . The method of  claim 1 , wherein the HER2-amplified cancer is selected from the group consisting of breast, colon, endometrial, cervical, urothelial, lung (including, non-small cell lung cancer), ovarian, gastric, gastroesophageal junction (GEJ), head and neck, biliary tract, prostate, and pancreatic cancer. 
     
     
         23 . The method of  claim 1 , wherein the HER2-amplified cancer is refractory to a treatment of trastuzumab, trastuzumab erntansine, pertuzumab, lapatinib, or MM-111. 
     
     
         24 . The method of  claim 1 , further comprising co-administering an additional therapeutic agent. 
     
     
         25 . The method of  claim 24 , wherein the additional therapeutic agent is an anti-HER2 therapeutic agent, a pan-ErbB inhibitor, or an anti-VEGF therapeutic agent. 
     
     
         26 . The method of  claim 25 , wherein the anti-HER2 therapeutic agent is selected from the group consisting of trastuzunab, trastuzumab emtansine, pertuzumab, lapatinib, and MM-11 (Merrimack Pharmaceuticals). 
     
     
         27 . The method of  claim 25 , wherein the pan-ErbB inhibitor is selected from the group consisting of afatinib, neratinib, and dacomitinib. 
     
     
         28 . The method of  claim 25 , wherein the anti-VEGF therapeutic agent is selected from the group consisting of bevacizumab, ranibizumab, lapatinib, sunitinib, sorafenib, axitinib, and pazopanib. 
     
     
         29 . The method of  claim 24 , wherein the additional therapeutic agent is selected from the group consisting of temsirolimus; paclitaxel; ASLAN001 (also, ARRY-543); vorinostat; doxorubicin; cyclophosphamide; cisplatin; docetaxel; dasatinib; trastuzumab and docetaxel; pertuzumab and docetaxel; doxorubicin, cyclophosphamide and paclitaxal; and doxorubicin, cyclophosphamide and 5-FU.